Fig. 3.
Fig. 3. Distribution of HSC, FC, and CD8+ T cells in (A through C) bone marrow and (D through F) spleen of B10.BR mice treated with FL alone (10 μg/mouse; day 1 to 10); G-CSF alone (7.5 μg/mouse; day 4 to 10); or FL + G-CSF. Animals (n = 6 per group) were euthanized before, on day 7, or day 10 of growth factor administration. Long bones and spleens were obtained and processed for each individual animal. Bone marrow cells and splenocytes were analyzed for the percentage of HSC (▪) (lineage−/Sca-1+/c-kit+), FC (□) (CD8+/βTCR−/γδTCR−), and CD8+ T cells (▧) (CD8+/βTCR+) by flow cytometry. Results represent the mean (SEM) percentage on total bone marrow and total splenocytes. Percentages of HSC and FC that differed significantly from day 0 values are marked (* P < .05 or ** P < .005).

Distribution of HSC, FC, and CD8+ T cells in (A through C) bone marrow and (D through F) spleen of B10.BR mice treated with FL alone (10 μg/mouse; day 1 to 10); G-CSF alone (7.5 μg/mouse; day 4 to 10); or FL + G-CSF. Animals (n = 6 per group) were euthanized before, on day 7, or day 10 of growth factor administration. Long bones and spleens were obtained and processed for each individual animal. Bone marrow cells and splenocytes were analyzed for the percentage of HSC (▪) (lineage/Sca-1+/c-kit+), FC (□) (CD8+/βTCR/γδTCR), and CD8+ T cells (▧) (CD8+/βTCR+) by flow cytometry. Results represent the mean (SEM) percentage on total bone marrow and total splenocytes. Percentages of HSC and FC that differed significantly from day 0 values are marked (* P < .05 or ** P < .005).

Close Modal

or Create an Account

Close Modal
Close Modal